BioCentury
ARTICLE | Clinical News

Allergy Therapeutics grass pollen program hits snag

June 28, 2016 1:28 AM UTC

Allergy Therapeutics plc (LSE:AGY) lost 3.50p (15%) to 20p on Monday after it said it would need to conduct another dose-ranging study of grass allergy therapy GrassMATAMPL next year before beginning a U.S. Phase III trial. The company said it failed to determine a recommended dose based on a Phase II dose-ranging study.

GrassMATAMPL is an ultra-short course allergen-specific immunotherapy comprising modified allergens, microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL). The company markets the product in Europe as Pollinex Quattro Grass. ...